FILTER
LATEST INTERVIEWS
Martin van Gemert
MANAGING DIRECTOR, MINCON WEST AFRICA
Mincon comments on its business with the mining sector in West Africa.
Tim Gabruch
VP COMMERCIAL, DENISON MINES CHIEF COMMERCIAL OFFICER, URANIUM PARTICIPATION CORPORATION
“Phoenix is the highest-grade undeveloped uranium deposit in the world, with an average grade of 19.1% and 59.7 million pounds U3O8 in probable reserves (141,000 tonnes).”
Lorenzo Fiorillo
EVP WEST AFRICA, ENI
ENI updates GBR on the progress of its operations across Sub-Saharan Africa.
Chivambo Mamadhusen
CEO, GRUPO VIDERE
Grupo Videre looks at the massive LNG developments in Northern Mozambique from the perspective of a service company.
Dave Lawson
PRESIDENT MINING & MINERALS, WOOD GROUP
Wood Group provides a winde array of mining services to its clients in Chile.
Ricus Grimbeek
PRESIDENT AND CEO, TREVALI
Trevali Mining examines the challenges of mining in the time of COVID-19 and how efforts to reduce costs have been rewarded.
Ricardo Cuetos
VP AMERICAS STANDARD PRODUCTS, INEOS STYROLUTION
INEOS Styrolution explains the current market dynamics of the America’s and how it’s various units are coping.
Mike Brown
CEO, CHESSER RESOURCES
Chesser Resources is upbeat about its Diamba Sud gold resource in Eastern Senegal.
Frédéric Heintz
DEPUTY GENERAL MANAGER, PETROMAR
Petromar speaks of the outlook for Angola’s oil and gas service industry for the next two years.
Danny Callow
CEO, AFRICAN GOLD GROUP (AGG)
African Gold Group explains its ambitions in West Africa where it’s Kobada gold mine is under construction.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
